Long‐term effectiveness of eliglustat treatment: A real‐world analysis from the International Collaborative Gaucher Group Gaucher Registry
American Journal of Hematology · 2024-08 · 99 (8) · 1500-1510
DOI: 10.1002/ajh.27347 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 30.04.2024. Verfasst von Pramod K Mistry und 9 weiteren Autor:innen. Beteiligte Einrichtung: Yale University School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Gaucher Disease, Registries, Pyrrolidines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi.
Abstract (Originalsprache)
Gaucher disease type 1 (GD1) is known for phenotypic heterogeneity and varied natural history. Registrational clinical trials enrolled narrowly defined phenotypes, but greater diversity is encountered in clinical practice. We report real‐world outcomes with long‐term eliglustat treatment in adults with GD1 in the International Collaborative Gaucher Group Gaucher Registry. Among 5985 GD1 patients in the Registry as of January 6, 2023, 872 started eliglustat at ≥18 years old; of these, 469 met inclusion criteria. We compared clinical parameters at eliglustat initiation (i.e., baseline) and follow‐up in treatment‐naïve patients and used linear mixed models to estimate annual change from baseline in parameters among patients who switched to eliglustat after ≥1 year on enzyme replacement therapy. Over 4 years of follow‐up in non‐splenectomized treatment‐naïve patients, hemoglobin and platelet count increased, liver and spleen volume decreased, and total lumbar spine bone mineral density (BMD) Z‐score decreased slightly. Among non‐splenectomized switch patients, on average, hemoglobin decreased −0.030 (95% CI: −0.053, −0.008) g/dL ( N = 272) and platelet count increased 2.229 (95% CI: 0.751, 3.706) × 10 3 /mm 3 ( N = 262) annually up to 10 years; liver volume decreased (−0.009 [95% CI: −0.015, −0.003] MN) ( N = 102) and spleen volume remained stable (−0.070 [95% CI: −0.150, 0.010] MN) ( N = 106) annually up to 7 years; and total lumbar spine BMD Z ‐score increased 0.041 (95% CI: 0.015, 0.066) ( N = 183) annually up to 8 years. Among splenectomized switch patients, clinical parameters were stable over time. These long‐term, real‐world outcomes are consistent with the eliglustat clinical trials and emerging real‐world experience across the GD phenotypic spectrum.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Yale University School of Medicine, New Haven, Connecticut, USA.
- Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
- Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Katholisches Klinikum Oberhausen, Oberhausen, Germany.
- Sanofi, Cambridge, Massachusetts, USA.
ORCID-Profile: Pramod K Mistry, Manisha Balwani, Priya S Kishnani
Förderung
- Sanofi
Zitieren
APA
Mistry, P. K., Balwani, M., Charrow, J., Lorber, J., Niederau, C., Carwile, J. L., Oliveira-Dos-Santos, A., Perichon, M. G., Uslu Cil, S., & Kishnani, P. S. (2024). Long‐term effectiveness of eliglustat treatment: A real‐world analysis from the International Collaborative Gaucher Group Gaucher Registry. American Journal of Hematology, 99(8), 1500-1510. https://doi.org/10.1002/ajh.27347
Vancouver
Mistry PK, Balwani M, Charrow J, Lorber J, Niederau C, Carwile JL, et al. Long‐term effectiveness of eliglustat treatment: A real‐world analysis from the International Collaborative Gaucher Group Gaucher Registry. American Journal of Hematology. 2024;99(8):1500-1510. doi:10.1002/ajh.27347
BibTeX
@article{Mistry2024,
author = {Mistry, Pramod K and Balwani, Manisha and Charrow, Joel and Lorber, Jeremy and Niederau, Claus and Carwile, Jenny L and Oliveira-Dos-Santos, Antonio and Perichon, Maria Gabriela and Uslu Cil, Sefika and Kishnani, Priya S},
title = {Long‐term effectiveness of eliglustat treatment: A real‐world analysis from the International Collaborative Gaucher Group Gaucher Registry},
journal = {American Journal of Hematology},
year = {2024},
volume = {99},
number = {8},
pages = {1500--1510},
doi = {10.1002/ajh.27347}
}
EUVIMED